Abstract
The bispecific monoclonal antibody (bsAb) BIS-1 combines a monoclonal-antibody(mAb)-defined specificity for the CD3 complex, as present on all T lymphocytes, with a mAb-defined specificity for the pancarcinoma/epithelium associated glycoprotein EGP-2. In vitro studies indicate that BIS-1 can direct T lymphocytes to kill EGP-2-positive tumour target cells. T cell pre-activation is necessary for this activity and can be obtained either via incubation of isolated peripheral blood mononuclear cells with CD3 mAb, followed by short culturing in recombinant interleukin-2-containing medium, or via costimulation with CD5- and CD28-based bsAb. Clinical application of BIS-1 was started in a pilot study in which carcinoma patients suffering from malignant ascites or intrapleural effusion were treated. In this study, ex vivo activated autologous lymphocytes were applied locally, i.e. intraperitoneally or intrapleurally, in the presence of BIS-1. Local inflammation and antitumour activity were observed, whereas no or only minor systemic toxicity was seen in these patients. Intravenous administration of BIS-1 F(ab')2 in combination with subcutaneously given recombinant interleukin-2 (i.v. bsAb/rIL-2 treatment) induced transient but considerab...Continue Reading
Citations
Sep 15, 2006·Journal of Immunotherapy·Christian EnsingerKurt W Schmid
Oct 13, 2015·Current Opinion in Hematology·Divaya Bhutani, Lawrence G Lum
Apr 9, 2013·Future Oncology·Alessandro SattaMariangela Figini
Mar 1, 2000·Gene Therapy·K W LiaoS R Roffler
Jul 21, 1999·FEBS Letters·M AltR E Kontermann
Jul 10, 2004·Human Gene Therapy·Michele W L TengPhillip K Darcy
Dec 1, 2007·Journal of Immunotherapy·Klaus BrischweinPatrick A Baeuerle
Nov 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alja J StelSebo Withoff
Sep 1, 2008·Expert Opinion on Drug Discovery·Lawrence G Lum, Zaid Al-Kadhimi
Sep 14, 2016·Oncoimmunology·Djoke HendriksEdwin Bremer
Sep 18, 2018·Oncoimmunology·Iris KoopmansWijnand Helfrich
Nov 5, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Lawrence G Lum, Archana Thakur
Jul 24, 2014·Molecular Cancer Therapeutics·Edmund A RossiDavid M Goldenberg
Jan 21, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·G MolemaL F de Leij
Apr 18, 2014·Molecular Pharmaceutics·Haiming LuoWeibo Cai